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Abstract Deficiency of argininosuccinate synthetase (ASS) 
causes citrullinemia. Type II citrullinemia is found in most pa- 
tients with adult-onset citrullinemia in Japan, and ASS is defi- 
cient specifically in the liver. Previous studies have shown that the 
decrease of hepatic ASS activity is caused by a decrease in 
enzyme protein with normal kinetic properties and that there are 
no apparent abnormalities in the amount, translational activity, 
and nucleotide sequence of hepatic ASS mRNA. Recent results 
of homozygosity testing indicate that the primary defect of type 
II citrullinemia is not within the ASS gene locus. In this present 
work, to understand the pathogenesis and pathophysiology oftype 
II citrullinemia, we have characterized the alterations of gene 
expression in the liver of type II patients using the recently devel- 
oped mRNA differential display method. Some cDNA bands 
expressed ifferently in type 1I citrullinemia patients and control 
were selected, cloned, and sequenced. Nucleotide sequence analy- 
sis and homology searching revealed an interesting clone which 
has 99% homology with the human pancreatic secretory trypsin 
inhibitor (hPSTI). Northern blot and RT-PCR analyses howed 
that the expression of hPSTI mRNA increased significantly in 
the liver of all type II patients tested. Furthermore, the concentra- 
tion of hPSTI protein was found to be higher in the liver of type 
II citrullinemia than in control. These results suggest hat hPST! 
may be related to the primary defect of type II citrullinemia and 
may be useful as a diagnostic marker, although the detailed 
mechanism of the high expression of hPSTI mRNA in type 11 
liver is not yet known. 
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1. Introduction 
Citrullinemia is an autosomal recessive disease caused by 
deficiency of argininosuccinate synthetase (ASS; EC 6.3.4.5). 
The clinical, biochemical, and molecular aspects of citrulline- 
mia and their heterogeneity have been reviewed elsewhere [14]. 
Saheki et al. [2] analyzed the enzyme abnormalities in Japanese 
citrullinemia patients and classified into three types. The classi- 
cal form (type I and III) is found in most patients with neonatal/ 
infantile-onset citrullinemia. The enzyme defect in the classical 
form is found in all tissues and/or cells where ASS is expressed. 
21 mutations in ASS mRNA and 22 mutations in ASS gene 
have been identified in human classical citrullinemia ([5-11]; 
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Kakinoki et al., manuscript in preparation). We can now diag- 
nose 11 of 22 mutations in classical citrullinemia using genomic 
DNA by Southern blot analysis and by a combination of 
polymerase chain reaction (PCR) and restriction enzyme diges- 
tion ([6,7,10,11]; Kakinoki et al., manuscript in preparation). 
We have also described a different type of citrullinemia, 
which occurs in association with decreased ASS activity and 
protein in the liver but normal ASS levels in other tissues, such 
as kidney, brain, and fibroblasts [2,12 16]. Most patients uffer 
from sudden disturbance of consciousness, such as disorienta- 
tion, restlessness and coma. This unique citrullinemia was clas- 
sified as type II [2], and most patients with adult-onset cit- 
rullinemia belonged to type II. The symptoms, such as high 
concentration of serum citrulline, slight increase of serum 
arginine, and hyperammonemia, resulted from the specific de- 
crease in hepatic ASS level [2] and were corrected by liver 
transplantation i  two patients ([17]; Kawamoto et al., manu- 
script in preparation). In adult-onset type 11 citrullinemia with 
liver-specifc deficiency, the decreased hepatic ASS showed ki- 
netic properties, heat stability and specific activity of ASS (aci- 
tivity/CRM) comparable to control [2,12-16,18 21]. The heter- 
ogeneous distribution of ASS in the liver of type II citrullinemia 
patients was tbund by immunohistochemical study [2,22,23]. 
Analysis of mRNA from type II citrullinemia patients revealed 
that hepatic ASS mRNAs have: (a) a translatable activity in 
vitro when a cell-free translation system is used; (b) no decrease 
in amount; (c) no structural abnormality detectable by North- 
ern blotting and Sl-nuclease digestion; and (d) no mutation 
detectable by nucleotide sequence analysis [2,24-27]. 
We have analyzed almost 100 patients with adult-onset type 
II citrullinemia, since Saheki et al. reported the first cases in 
1981 [12], and the proportion of type II citrullinemia patients 
from consanguineous parents is approximately 20%. Homozy- 
gosity mapping analysis of the affected patients from consan- 
guineous parents uggested that the abnormality is not within 
the ASS gene locus and that the primary defect is located in 
another unknown gene [27]. 
In order to understand the pathogenesis and the detailed 
pathophysiology and to identify changes in gene expression, we 
used a newly developed method called mRNA differential dis- 
play [28] to select unique genes expressed ifferentially in the 
liver of patients with type II citrullinemia nd other diseases. 
2. Materials and methods 
2.1. Patients 
Biopsy or autopsy liver specimens included in the present paper were 
obtained from 11 patients with adult-onset type lI citrullinemia. We 
diagnosed them as type I1 citrullinemia under criteria described previ- 
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ously [2,27]; a high concentration f serum citrulline, a slight increase 
in serum arginine, an increase in the ratio of threonine to serine in 
serum, and a decrease in hepatic ASS activity with normal kinetic 
properties, together with no decrease in renal and/or fibroblast ASS 
activity. Biochemical data and molecular aspects of the patients (except 
AP-78 and AP-86) have already been reported [16,17,19-21,23-25,27]. 
The hepatic ASS activities of patients AP-78 and AP-86 were 3.3% and 
6% of control, respectively. The serum citrulline levels of both patients 
were 400-500 nmol/ml (normal 2040 nmol/ml). For patients AP-61 
[17] and AP-86 (Kawamoto et al., manuscript in preparation), liver 
transplantation was performed as therapy immediately after diagnosis 
of type II citrullinemia. Patient AP-29 with type II citrullinemia was 
positive for hepatitis B-virus surface antigen, but other type II patients 
were negative for HB- and HC-virus. The histological findings of liver 
specimens from patients with type II citrullinemia were usually fatty 
infiltration, fibrosis, and no pathological signs [2,17,23], but some cases 
had cirrhosis (AP-29) and chronic hepatitis (AP-30). 
Liver specimens used as controls in the present study were as follows: 
from a patient (AP-82) with type I citrullinemia of adult-onset [10,11], 
a patient (C-76) with angioma and positive for HB-virus, a patient 
(C-81) with rectal cancer, diabetes mellitus and old myocardial infarc- 
tion, a patient (C-100) with intrahepatic calculus, and a patient (C-104) 
with gall bladder calculus. Non-tumor portions urrounding the hepatic 
carcinoma of a patient (C-201) with liver cirrhosis and of patients (C-82, 
C-83 and C-84) with metastatic hepatic ancer transferred from extra- 
hepatic cancer were used as controls, too. To compare the level of 
human pancreatic secretory trypsin inhibitor (hPSTI) expression, 
tumor and non-tumor portions were obtained uring surgery from 2 
patients (C-l; negative for virus, C-2; positive for HC-virus) with hepa- 
tocellular carcinoma (HCC) and from a patient (C-3 or C-4) with 
metastatic hepatic ancer which originated from colorectal and gastric 
cancers, respectively. 
2.2. Extraction of RNA and removal of DNA contamination from RNA 
Total RNA was isolated from liver specimens as described by 
Chomczynski and Sacchi [29] and Kobayashi et al. [5 7,9-11,24-27]. 
The RNA (50/zg) was treated with 10 units of DNase I using Mes- 
sageClean Kit (GenHunter Co.). After extraction with phenol/chloro- 
form and ethanol precipitation, the RNA was redissolved in DEPC- 
treated water. 
2.3. Differential display of mRNA 
Differential display PCR was carried out on the type [I patient and 
control RNAs using the method of Liang and Pardee [28] and the 
GenHunter Corporation mRNA differential display system 
(Brookline). The following oligonucleotide primers were used to ana- 
lyze the RNAs present. Four oligo-d(T) primers, (T)I2MN were used 
for reverse transcription and as the Y-PCR primer. The 5' primers for 
PCR were 20 kinds ofAP-primer, AP-1 to AP-20, each constituted from 
10mer. Polyacrylamide 6% gels (Long Ranger gel, AT Biochem) were 
run to separate the amplified bands labelled with [~-35S]dATP (New 
England Nuclear). Re-amplification of the interest bands was carried 
out with the same primers as used in the initial reaction. Amplified PCR 
products were cloned into a pCR-II vector using theTA cloning system 
(Invitrogen) for further analysis. Double-stranded DNA was sequenced 
by the dideoxy chain-termination method using Sequenase (United 
States Biochemical) and 35S-labelled ATP [6,7,9-11] and/or using the 
Hitachi model SQ-5500 DNA auto-sequencer by using ATaq fluores- 
cent dye-primer cycle sequencing kit (Amersham) and Texas-red la- 
belled primer. 
2.4. Northern blotting and RT-PCR 
Total RNA (20/zg) was analyzed by Northern blotting as previously 
described [5,25]. Specific probe for hPSTI was generated by labelling 
cloned cDNA fragments with [ct-3ZP]dCTP and random prime DNA 
labelling kit (Amersham). After hybridization at 42°C and high-strin- 
gency washing at 60°C in 0,3 M NaCI/0.03 M trisodium citrate/0.1% 
SDS, the blots were exposed to Fuji X-ray film for 6 days with intensi- 
ring screens. 
For reverse transcription-polymerase chain reaction (RT-PCR), 
first-strand cDNA was synthesized from 5 ~g of total RNA using 
reverse transcriptase and oligo-d(T)~8 in 20/.tl of final volume. Each 1 pl 
of first-strand cDNA sample was used for the amplification of the 
hPSTI and C-reactive protein (CRP) cDNA and 1 pl of 200-times 
diluted first-strand cDNA sample was used for the PCR of albumin 
mRNA. Oligonucleotides used as PCR-primers were 5'-CGTAG- 
GATCCAT ATGAAGGTAACAGGCATCTTTC-3' and 5'-CGTA- 
GGATCCAGTCAGGCCTCGCGGTGA-Y for hPSTI (underlined 
sequences are from hPSTI cDNA) [30], 5'-TGACCAGCCTCTCTC- 
ATGCT-Y and 5'-GAGCAGGCCTGCAATGCATA-Y for CRP [31], 
and 5'-TCTATCCGTGGTCCTGAACC-Y and 5'-CTCATGGTAG- 
GCTGAGATGC-Y for albumin [32], respectively. Amplification of the 
cDNA was carried out for 25 cycles at 95°C for 1 min, 60°C for 0.5 1 
min, and 72°C for 2-3 min as in previous reports [7,9-11]. The PCR- 
products were electrophoresed on a 2% agarose gel. 
2.5. Determination of hepatic hPSTI protein 
Tissue extracts were prepared by homogenizing specimens with an 
adequate volume of 0.15 M KC1 containing 50 mM Tris-HC1, pH 7.5. 
Insoluble fractions were discarded by centrifugation. The concentration 
of hPSTI protein was measured by RIA system supplied from Shionogi 
Pharmaceutical Co. (Osaka) and the hPSTI content in tissues was 
estimated and expressed as ~tg/g wet weight. 
3. Results 
Total RNA was extracted from liver specimens of three pa- 
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Fig. 1. Differential display comparing RNA from type II citrullinemia 
patients and controls. Total RNA was extracted from liver specimens 
and subjected to differential mRNA display analysis as described in 
section 2. Autoradiogram ofamplified [ct-35S]dATP-labelled PCR prod- 
ucts are shown. The primers used were AP-15, 5'-AGGGCCTGTT-Y 
(Y-primer) and 5'-T~2MA-Y (Y-primer). Candidate cDNA signal which 
demonstrated altered expression by differential display is marked by 
arrow. Lanes 1 to 3 are control, C-81, C-83 and C-84; lanes 4 to 6 are 
type II patients, AP-29, AP-30 and AP-38, respectively. 
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the other hand, the mRNA level of CRP which is a major acute 
phase reactant (APR) showed a slight tendency to be lower in 
type II patients than in controls but there was no significant 
difference between them. There was no significant difference in 
albumin mRNA level either, as shown in Fig. 3. 
In order to investigate whether highly expressed hPSTI 
mRNA is translatable or not, we determined the concentration 
of hPSTI protein in liver and tumor specimens by RIA (Table 
1). hPSTI protein was less than 0.01 #g/g wet tissue in the liver 
of control patients including noncancerous portions of liver 
from hepatoma patients and high level tumor portions from 
HCC, which agrees with previous reports [34,39]. As expected 
from the results of hPSTI mRNA analyses, the hPSTI protein 
level in the liver of most patients with type II citrullinemia 
tested was far higher but with a wider range than in cancerous 
tissues. 
4. Discussion 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Fig 2. Confirmation of hPST1 mRNA expression by Northern blot 
hybridization (A) and RT-PCR (B) analyses. (A) Total RNA extraction 
and Northern blot were carried out as described in section 2. The upper 
panel shows the autoradiogram of hPSTI mRNA. Ethidium bromide- 
stained RNA is shown below column. (B) First-strand cDNA was 
synthesized from 5 pg of total RNA by using reverse transcriptase and 
oligo-d(T)~8. Amplification of hPSTI mRNA was carried out as de- 
scribed in section 2. T and N denote tumor and non-tumor portions of 
liver from patients C-I to C-4 with hepatic ancer (lanes 1-8). Lanes 
9 to 13 are type II citrullinemia patients AP-78, AP-86, AP-29, AP-30 
and AP-38, and lanes 14 to 16 are control C-76, C-81 and C-83, re- 
spectively. 
tients with adult-onset type II citrullinemia (AP-29, AP-30 and 
AP-38). The control RNA preparations used for differential 
display were from a liver specimen of a patient with rectal 
cancer but no hepatic metastasis (C-81) and noncancerous he- 
patic portions of two patients with metastatic hepatic cancer 
(C-83 and C-84). Several cDNA bands were found to be differ- 
entially expressed on the gel electrophoresis (data not shown). 
A cDNA fragment selectively expressed in type II citrullinemia 
was shown in Fig. 1. This cDNA fragment (A-l 5) was extracted 
from the gel, PCR-amplified using a set of AP-15 as 5' primer 
and T~2MA as 3' primer, cloned into a pCR-II vector using the 
TA cloning system, and sequenced. From a homology search 
in GenBank, the nucleotide sequence from clone A-15 had 99% 
homology with the nucleotide sequence from 36 to 318 of 
human pancreatic secretory trypsin inhibitor (hPSTI) mRNA 
[30,331. 
It has been reported that PSTI mRNA is expressed highly 
in hepatic ancer and also other cancer tissues [34--38]. There- 
fore, we tested tumor portions and non-tumor portions of liver 
specimens from patients with HCC and two patients with 
metastatic hepatic ancer (one from colon cancer and the other 
from stomach cancer). By Northern blotting and RT-PCR 
analysis as shown in Fig. 2, we confirmed that the hPSTI 
mRNA was expressed in the hepatic tumor portion regardless 
of origin. The hPSTI mRNA estimated to be about 0.53 kb on 
Northern blot as reported previously [30], was found clearly in 
the liver of adult-onset type II citrullinemia. However, hPSTI 
mRNA was not detected or was at a low level in the non- 
cancerous hepatic portion of patients with hepatic ancer and 
liver specimens from other control patients (Figs. 2 and 3). On 
PSTI was first isolated from bovine pancreas in 1948 by 
Kazal et al. [40] and has been thought to exist only in the 
pancreas. Its role has been considered to be a specific inhibitor 
that prevents autoactivation f trypsinogen i the pancreas and 
pancreatic juice [41]. Later studies howed that PSTI was also 
expressed in some extrapancreatic normal tissues [39,4345] 
and in various cancers, including pancreatic [34], colorectal 
[35], gastric [36], lung [37], and hepatocellular [38] cancers. It 
was found that the serum concentration of immunoreactive 
PSTI is elevated after surgery, trauma and severe infection 
[45-47], suggesting that PSTI is an acute phase reactant. PSTI 
is expressed in the liver which secretes it into the blood in 
response to inflammatory cytokines, such as IL-6 [48,49]. These 
phenomena imply that PSTI has other physiological nd pa- 
thological roles in addition to the inactivation of trypsin. Sev- 
eral papers uggest that tumor-derived PSTI acts as autocrine 
or paracrine growth factor [46,50-54], and is associated with 
Table 1 
The contents of hPSTI protein in liver specimens oftype II citrullinemia 
and control patients and in tumor portions of liver from patients with 
hepatic ancer 
Patients hPSTI 
(flg/g wet weight) 
Type II citrullinemia AP-17 0.043 
AP-18 0.051 
AP-21 0.514, 0.377 
AP-27 0.659 
AP-30 <0.01 
AP-38 0.186 
AP-39 6.89, 5.98 
AP-61 0.385 
AP-78 0.063 
AP-86 0.025 
Control 
Tumor portion 
C-76 <0.01 
C-82 <0.01 
C-104 <0.01 
C-201 <0.01 
C-I <0.01 
C-2 <0.01 
C-3 <0.01 
C-1 0.323, 1.19 
C-2 <0.01 
C-3 0.018 
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Fig. 3. Expression patterns of hPSTI (A), CRP (B) and albumin (C) 
mRNAs in the liver of type II citrullinemia and control patients. All 
procedures of cDNA synthesis and the amplification are shown in Fig. 
2 and section 2. Lanes l to 7 are patients as control; AP-82 (adult-onset 
type 1 citrullinemia), C-76, C-81, C-82, C-83, C-84 and C-100, respec- 
tively. Lane 8 is DNA size marker. Lanes 9 to 17 are type II patients: 
AP- 17, AP-18, AP-21, AP-27, AP-29, AP-30, AP-38, AP-39 and AP-61, 
respectively. 
the tumor growth of stromal proliferation of fibrous tissues 
[36,37], although it has been reported recently that the evalua- 
tion of tumor-derived PSTI as a paracrine or autocrine growth 
factor is not definite and needs confirmation [55]. 
The hPSTI mRNA expression in type II citrullinemia pa- 
tients was equivalent to the level in hepatic cancer portions 
(Figs. 2 and 3), although the liver specimens of most type I1 
patients tested in the present paper did not show any histolog- 
ical appearance as cancer. It was suggested that the PSTI gene 
is regulated by the AP-I binding site and IL-6 responsive le- 
ment, and each region is active in hepatoma cells [38]. However, 
the biological implication of the high PSTI gene expression in 
hepatic ancer is not yet understood. We investigated the gene 
expression of CRP, a major acute phase reactant, by using 
RT-PCR method in the liver of type II patients although there 
is no sign for inflammation. The result showed that CRP 
mRNA is not increased in the liver of patients with type II 
citrullinemia (Fig. 3). This suggests that the high expression of 
hPSTI in the liver of type II citrullinemia s not related to acute 
phase reaction. The possibility can not be ruled out, however, 
that CRP levels may be increased in the serum of type II 
patients. It is known that the dramatic transcriptional induction 
of CRP by IL-6 is further enhanced by novel translational nd 
post-translational mechanisms, which eventually lead to a neg- 
ative-feedback loop in which CRP can downregulate its own 
levels during inflammatory responses [56]. In type II citrulline- 
mia, the relationship between the decrease in hepatic ASS- 
protein levels and the increase in PSTI mRNA has not yet been 
explained. As shown in Table 1, the contents of immunoreac- 
tive hPSTI in the liver of patients with type II citrullinemia 
except one patient (AP-30) showed 20-3,000 fold increases over 
the normal level (0.002 + 0.001/,tg/g wet weight liver) [39]. 
Finally, we conclude that PSTI may be useful as a diagnostic 
marker for adult-onset type II citrullinemia, although further 
experiments will be required to verify this. We are now investi- 
gating the specificity, usefulness and meaning of high PSTI 
expression i  type II citrullinemia patients by determining PSTI 
level in the serum and comparing it with the acute phase re- 
sponse, tumor and pancreatitis marker level. 
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